253 related articles for article (PubMed ID: 29180474)
21. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
22. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
24. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
25. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
[TBL] [Abstract][Full Text] [Related]
26. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
27. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
[TBL] [Abstract][Full Text] [Related]
28. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
Zhao B; Cheng X; Zhou X
Melanoma Res; 2018 Dec; 28(6):521-526. PubMed ID: 30192303
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
30. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
31. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
32. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
[TBL] [Abstract][Full Text] [Related]
33. MCM5 as a target of BET inhibitors in thyroid cancer cells.
Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity.
Sun L; Liu J; Yuan Y; Zhang X; Dong Z
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F469-F478. PubMed ID: 29767555
[TBL] [Abstract][Full Text] [Related]
35. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
36. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
37. Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake.
Kang JS; Cho D; Kim YI; Hahm E; Kim YS; Jin SN; Kim HN; Kim D; Hur D; Park H; Hwang YI; Lee WJ
J Cell Physiol; 2005 Jul; 204(1):192-7. PubMed ID: 15672419
[TBL] [Abstract][Full Text] [Related]
38. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
39. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
40. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
